A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : OA / oral anticoagulants

[Related PubMed/MEDLINE]
Total Number of Papers: 87
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   OA  (>> Co-occurring Abbreviation)
Long Form:   oral anticoagulants
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. AF
2019 Comparison of bipolar plasmakinetic transurethral enucleation and resection of prostate gland in patients receiving anticoagulants and/or platelet aggregation inhibitors. B-TURP, BPEP, BPO, PAI
2019 Perioperative Safety in Patient Under Oral Anticoagulation During Holmium Laser Enucleation of the Prostate. DOACs, HoLEP, VKAs
2019 Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. DOACs, FFP, PCC, VKAs
2018 Biobarcode assay for the oral anticoagulant acenocoumarol. ACL
2018 Enzyme-linked immunosorbent assays for therapeutic drug monitoring coumarin oral anticoagulants in plasma. ACL
2018 Factors associated with discontinuing or not starting oral anticoagulant therapy in older hospitalized patients with non-valvular atrial fibrillation. NVAF
2017 Clinical profile and outcomes in octogenarians with atrial fibrillation: A community-based study in a specific European health care area. AF, TE
2017 Current Management in Transurethral Therapy of Benign Prostatic Obstruction in Patients on Oral Anticoagulation: A Worldwide Questionnaire. ADP, BPO
10  2017 First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. LAAC, NVAF
11  2016 Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate in Patients on Oral Anticoagulants: A Retrospective Three-Centre Matched-Paired Comparison. ThuVARP, ThuVEP
12  2014 Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. BPO, IQR, ThuVEP
13  2014 Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice. AF, OR
14  2013 Aspirin versus anticoagulation in intra- and extracranial vertebral artery dissection. VAD
15  2013 Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. AF, TEE
16  2013 Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population. CYP4F2, DNA, RT-PCR
17  2013 The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation. CMBs, GRE, ICH, MRI, NVAF
18  2013 The order of draw: myth or science? ---
19  2012 Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. AF, MMS
20  2012 Dietary vitamin K intake and stability of anticoagulation with coumarins: evidence derived from a clinical trial. INR
21  2012 Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation. ACP, FU, LAAC, NVAF
22  2012 Long-term self-management of anticoagulation therapy after mechanical heart valve replacement in outside trial conditions. Conv-T, MHV, Self-M
23  2012 New guidelines for lupus anticoagulant: sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests. APTT, dPT, dRVVT, ICA, LA, SEN, SPC
24  2012 Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. LMWH, OR, sICH
25  2012 The effect of oral anticoagulation on the prevalence and management of haematuria in a contemporary Australian patient cohort. DRG, if any, LOS
26  2011 Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. BPH, PAI, TURP
27  2011 Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. PBAC
28  2011 Surgical management of BPH in patients on oral anticoagulation: transurethral bipolar plasma vaporization in saline versus transurethral monopolar resection of the prostate. PAI, TURP, TUVis
29  2011 [Hematoma of the rectus abdominis. experience of a primary care hospital]. HRA
30  2010 Differences in the INR evaluation of two different thromboplastins in patients with positivity to lupus anticoagulant in ongoing oral anticoagulation. APS, INR, LAC
31  2010 Ex vivo thrombin generation in patients with venous thromboembolic disease or atrial fibrillation on long-term oral anticoagulation. AF, FVIII, INR, PC, TAT, VTE
32  2010 Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy. BPH, TURP
33  2010 [Holmium laser enucleation of the prostate (HoLEP) in patients with continuous oral anticoagulation: first reported cases in Japan]. BPH, HoLEP, TURP
34  2009 Safety of holmium laser enucleation of the prostate in anticoagulated patients. HoLEP, INR, TURP
35  2009 Skeletal effects of oral anticoagulants. OC, VKA
36  2009 [Oral anticoagulants and atrial fibrillation]. AF
37  2009 [The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use]. ---
38  2008 Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. CYP2C9
39  2008 Warfarin anticoagulation intensity in specialist-based and in computer-assisted dosing practice. AF, INR, PHV, VTE
40  2007 Anticlotting drugs and regional anaesthetic and analgesic techniques: comparative update of the safety recommendations. ---
41  2007 Menorrhagia and minor bleeding symptoms in women on oral anticoagulation. ---
42  2007 Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. BPH, PVP
43  2007 [The insufficiency of low molecular weight heparin (LMWH) prophylaxis in patients with hereditary antithrombin (AT) deficiency]. AT, DVT, LMWH, PE
44  2006 Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. APTT, CI, RR, VTE
45  2006 Aspirin or anticoagulants in stenosis of the middle cerebral artery: A randomized trial. CI, MCA
46  2006 Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. ---
47  2006 Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. AP, CT, ED, ICH, MRS
48  2006 Therapeutic strategies after examination by transesophageal echocardiography in 503 patients with ischemic stroke. PFO, TEE
49  2006 [Pharmaceutical counselling and evaluation of the knowledge of hospitalized patients treated with anti-vitamin K drugs]. ---
50  2005 No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern Europeans. APTT, INR
51  2005 Pharmacogenetics of oral anticoagulants. ---
52  2005 [The frequency of risk factors of thromboembolic and hemorrhagic complications in patients treated with oral anticoagulants after heart valve replacement]. TE
53  2005 [Thromboembolic and haemorrhagic complications in patients treated with anticoagulants after artificial heart valve replacement. Risk factors dependent on quality of anticoagulant treatment]. TE
54  2004 Management of oral anticoagulant in clinical practice: a retrospective study of 187 patients. ---
55  2003 A prospective controlled study of a computer-assisted acenocoumarol dosage program. INRs
56  2003 Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. DTI, ECT, NP
57  2003 Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. LMWH, VTE
58  2003 Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. CI, LMWH, UFH, VTE
59  2003 Oral anticoagulant therapy in patients with coronary artery disease. CAD, MI
60  2003 Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients. PV, TIPSS
61  2003 Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. INR
62  2003 Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. HS, NNH, STROMA
63  2003 Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. ETP, OC, TF
64  2002 Resolution of left atrial thrombi with anticoagulant therapy in candidates for percutaneous transvenous mitral commissurotomy. LASEC, LAT, PTMC, TEE
65  2001 Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). ---
66  2001 Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. SIR
67  2001 Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. NRAF, RCT
68  2000 Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. CI
69  2000 Assessment of activated partial thromboplastin time and factor IX in subjects attending an anticoagulation clinic. APTT, FIX, INR
70  2000 Determination of activated protein C resistance in anticoagulated and lupus positive patients. APC, FV, LA, NP, RVV
71  2000 [Evidence-based guidelines for prevention and therapy of venous thromboembolism]. LMWH
72  2000 [LGM inferior vena cava filters--observation of 79 patients]. CTEPH, IVC, LMWH, PE, pts
73  1999 Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. DVT, LMWH
74  1999 Prevention of cardioembolic stroke: use of oral anticoagulants in patients with atrial fibrillation. AF, PA
75  1997 Prevention of recurrences after deep venous thrombosis: role of low-molecular-weight heparins. DVT, LMW, UF
76  1997 [Effectiveness of anticoagulant oral treatment in patients with thrombus in left ventricle after acute myocardial infarction]. AMI, LVMT
77  1995 Equal effectiveness of very-low-intensity anticoagulation and standard low-intensity anticoagulation: a pilot study. INRs
78  1993 [Anticoagulant treatment and pregnancy. Apropos of 47 cases]. ---
79  1992 [Oral anticoagulants in clinical practice]. ---
80  1990 A computerized regulation of dosage in oral anticoagulant therapy. PHV
81  1989 The optimal therapeutic range for oral anticoagulant treatment as suggested by fibrinopeptide A (FpA) levels in patients with heart valve prostheses. FPA, INR
82  1985 One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. DVT
83  1985 Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. AE, DCMP, INR, PE
84  1984 [Evaluation of a new chromogenic method for measuring prothrombin time in the control of oral anticoagulant therapy]. ---
85  1983 Oral anticoagulant in patients surviving myocardial infarction. A new approach to old data. MI
86  1980 Monitoring of oral anticoagulation by an amidolytic factor X assay. A long-term study in 42 patients. ---
87  1979 [Control of oral anticoagulation: comparison between Quick and colorimetric factor X determination in 107 patients]. PT